Cuorips Inc. (4894.T)
JPY 7680.0
(-9.11%)
JPY 7680.0
(-9.11%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.18 Billion JPY | 72.4% |
| 2022 | 3.58 Billion JPY | -11.31% |
| 2021 | 4.04 Billion JPY | -7.32% |
| 2020 | 4.36 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.01 Billion JPY | -2.82% |
| 2023 Q2 | 6.41 Billion JPY | 5.58% |
| 2023 FY | 6.18 Billion JPY | 72.4% |
| 2023 Q4 | 6.18 Billion JPY | -0.78% |
| 2023 Q3 | 6.23 Billion JPY | -2.77% |
| 2023 Q1 | 6.07 Billion JPY | 69.26% |
| 2022 FY | 3.58 Billion JPY | -11.31% |
| 2022 Q3 | - JPY | 0.0% |
| 2022 Q4 | 3.58 Billion JPY | 0.0% |
| 2021 FY | 4.04 Billion JPY | -7.32% |
| 2020 FY | 4.36 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 6.14% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -410.534% |
| GNI Group Ltd. | 62.39 Billion JPY | 90.088% |
| Linical Co., Ltd. | 18.53 Billion JPY | 66.641% |
| Trans Genic Inc. | 9.81 Billion JPY | 36.961% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -9.772% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 10.961% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -6.334% |
| AnGes, Inc. | 28.89 Billion JPY | 78.594% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -613.123% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 96.066% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -282.108% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -21.956% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -42.181% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -154.217% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -160.589% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 10.758% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -253.12% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -21.614% |
| PeptiDream Inc. | 67.12 Billion JPY | 90.786% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -203.085% |
| Ribomic Inc. | 3.54 Billion JPY | -74.353% |
| SanBio Company Limited | 5.04 Billion JPY | -22.536% |
| Healios K.K. | 15.15 Billion JPY | 59.19% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -402.719% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -105.064% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -319.545% |
| StemRIM | 9.08 Billion JPY | 31.886% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 10.102% |
| FunPep Company Limited | 2.49 Billion JPY | -148.27% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -136.18% |
| Stella Pharma Corporation | 3.82 Billion JPY | -61.878% |
| TMS Co., Ltd. | 3.55 Billion JPY | -73.985% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -7.022% |
| K Pharma,Inc. | 3.31 Billion JPY | -86.63% |
| Takara Bio Inc. | 123.2 Billion JPY | 94.98% |
| ReproCELL Incorporated | 9.05 Billion JPY | 31.68% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -127.772% |
| StemCell Institute Inc. | 6.54 Billion JPY | 5.477% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 11.505% |
| CellSeed Inc. | 2.46 Billion JPY | -150.824% |